Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence and Incidence of Acromegaly and Pituitary Tumors
4.2.2 Growing Awareness Regarding Acromegaly Disease Worldwide
4.2.3 Technological Advancements in Development of New Drugs for Acromegaly
4.3 Market Restraints
4.3.1 Complications Associated with the Treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product Type
5.1.1 Somatostatin Analogs
5.1.2 Growth Hormone Receptor Antagonist (GHRA)
5.1.3 Dopamine Agonists
5.1.4 Other Product Types
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc
6.1.2 Novartis AG
6.1.3 Validus Pharmaceuticals LLC
6.1.4 Ipsen
6.1.5 Chiasma, Inc
6.1.6 Crinetics Pharmaceuticals
6.1.7 Ionis Pharmaceuticals Inc
6.1.8 Midatech Pharma Plc
6.1.9 ADVANZ PHARMA
6.1.10 Amolyt Pharma


7 MARKET OPPORTUNITIES AND FUTURE TRENDS